Taste disturbances
3
We conclude that prophylaxis with intravenous acyclovir significantly reduced the risk of both cytomegalovirus infection and
High-dose acyclovir and (500 mg/m 2 3 times daily) valacyclovir prophylaxis (2 g 3-4 times daily) have been shown in earlier studies to reduce the risk for CMV
, 1985) so that this compound can also inhibit CMV
If you have weakened immunity, you may benefit from taking antiviral medication to prevent CMV disease
CMV Ig-treated patients tended to have less severe disease without any apparent reduction in infection incidence
The objective of this review was to summarize the recent literature describing the current burden of disease due to herpesviruses in the antiviral and transplant era; describe
Acyclovir is FDA-approved to treat genital herpes and HSV encephalitis
Taking acyclovir will not prevent you from passing genital herpes to your sexual partner
Go to: 3
High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative Foscarnet is a medication used to manage and treat CMV, HSV, and VZV viral infections in AIDS and immunocompromised patients
The time to CMV disease was significantly prolonged in patients on acyclovir as compared to patients on placebo (P=0
Given the high rate of infection in patients at risk, we infer that high-dose acyclovir does not prevent CMV infection in our setting of renal transplantation
19 However, the most recent trial in the preemptive therapy era did not demonstrate an effect on CMV disease and survival
The remit of this chapter is to summarize what is known about licensed antiviral drugs for CMV
Acyclovir (9- [2-hydroxymethyl]guanine) is a nucleoside analog that selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV)
Formulary Considerations for Drugs Used to Prevent Cytomegalovirus Disease - Medscape - Dec 01, 2003
We evaluated high-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients